Respiration (physiology)

China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask

Retrieved on: 
Wednesday, December 28, 2022
Mortality, Fluid mechanics, NYSE, Vehicle registration certificate, Atmosphere, Degenerative disease, Respiration (physiology), COVID-19, Blood, Quarantine, CNS, N95, City, Incidence, GMP, Research, Fine chemical, Pharmaceutical industry

HAIKOU, China, Dec. 28, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the launch of N95 medical protective mask ("N95 mask").

Key Points: 
  • HAIKOU, China, Dec. 28, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the launch of N95 medical protective mask ("N95 mask").
  • N95 Mask is a medical-level protection mask.
  • The number of COVID-19 infected people has exploded in all parts of China, and the demand of medical institutions and the public for high-level medical protective masks has increased significantly.
  • Our fast reaction in expanding our product lines to N95 medical protective masks have demonstrated our firm commitment to providing excellent health products for the public."

Wine Country Cannabis Brand Garden Society Launches New THCV-Rich Kiwi Lime Sauvignon Blanc Gummies

Retrieved on: 
Wednesday, December 14, 2022
Respiration (physiology), Woman, Liver, Alpine Garden Society, CMO, Rosette, Cannabis, Wine Country, THC, Sibling, Cannabinoid, Tetrahydrocannabivarin, Appetite, Nanotechnology, Warner, THCV, CBD, Mouth, Risk, Anxiety, Medicinal plants, Coffee, Drug

Cloverdale, CA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Garden Society , a popular women-owned California Wine Country cannabis brand featuring craft edibles and sun grown pre-rolls, has introduced a new THCV-based flavor and effect to their lineup of full spectrum gummies inspired by Wine Country.

Key Points: 
  • Cloverdale, CA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Garden Society , a popular women-owned California Wine Country cannabis brand featuring craft edibles and sun grown pre-rolls, has introduced a new THCV-based flavor and effect to their lineup of full spectrum gummies inspired by Wine Country.
  • Garden Society’s gummies are all gluten free, come in packs of 2 or 20, and are available today in dispensaries across California .
  • Dedicated to creating a new perspective on cannabis, Garden Society’s customers enjoy premium cannabis with an expected experience.
  • The new Wine Country Gummies offer customers the same trusted Garden Society experience delivered by their cannabis-infused chocolates and pre-roll Rosettes, available in both full-flower cannabis and hash -infused.

VectivBio Announces Results of Extraordinary General Meeting

Retrieved on: 
Friday, December 9, 2022
Extraordinary general meeting, Acquisition, Respiration (physiology), MMA, Congenital disorders of amino acid metabolism, Manufacturing execution system, Degenerative disease, Short bowel syndrome, Propionic acidemia, NAMS, Community of Metros, Coenzyme A, University of Groningen, Growth, General partnership, Business administration, Pantetheine, University, Novartis, International business, Patient, SBS, Fine chemical

BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022.

Key Points: 
  • BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022.
  • Mr. Wouter Joustra brings a breadth of capital markets and investment experience in the life sciences investment industry to VectivBio.
  • He joined Forbion, a leading European life sciences venture capital firm, in October 2019, where he is currently General Partner.
  • His deep experience in life-science capital markets will benefit VectivBio as we enter our next stage of growth,” said Tom Woiwode, VectivBio Board Chairman.

Panavance Therapeutics to Participate at the Virtual Investor Innovations in Oncology Spotlight Event

Retrieved on: 
Monday, December 5, 2022
Respiration (physiology), Melanoma, Virtual, Quality of life, Breast, Pancreatic cancer, Ovarian cancer, FDA, Ed, Trial of the century, AG, Chemische Industrie Uithoorn, Therapy, Patient, Pharmaceutical industry, Panaveli

In addition to the moderated portion of the event, investors and interested parties will have the opportunity to submit questions.

Key Points: 
  • In addition to the moderated portion of the event, investors and interested parties will have the opportunity to submit questions.
  • The Company will answer as many questions as possible during the event.
  • Panavance Therapeutics Inc. is a privately-held, clinical-stage pharmaceutical company developing a novel oncology platform focused on improving the effectiveness of cancer treatments and quality of life for patients.
  • Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate.

Environmental Monitoring: Evaluating Cellular Response Pathways in Complex Mixtures, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, December 5, 2022
Kleiber's law, Pennsylvania State University, Food, Lipid, Unresolved complex mixture, Central nervous system, Workflow, Doctor of Philosophy, Pharmacology, Xenobiotic, Biophysical environment, Research, Respiration (physiology), Toxicology, Assay, Pharmaceutical industry, Medicine

TORONTO, Dec. 5, 2022 /PRNewswire-PRWeb/ -- Cell-based in vitro bioassays have been used in environmental monitoring to detect and quantify the presence of micropollutants in water samples. These assays provide scientists with a rapid, sensitive and cost-effective tool for evaluating the impact that environmental contaminants may have on biological activity.

Key Points: 
  • These assays provide scientists with a rapid, sensitive and cost-effective tool for evaluating the impact that environmental contaminants may have on biological activity.
  • However, the complexity of chemical mixtures in environmental matrices makes it difficult to choose which cellular response pathways to evaluate.
  • In this webinar, the featured speaker will review recent environmental toxicology research that employs an alternative workflow for evaluating water samples.
  • For more information, or to register for this event, visit Environmental Monitoring: Evaluating Cellular Response Pathways in Complex Mixtures .

VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders

Retrieved on: 
Wednesday, November 16, 2022
COVID-19, EST, MMA, Short bowel syndrome, Proxy, Propionic acidemia, SBS, Federal Council (Switzerland), Degenerative disease, Patient, Exercise, Respiration (physiology), Manufacturing execution system, Security (finance), Extraordinary general meeting, Congenital disorders of amino acid metabolism, CET, Community of Metros, Coronavirus, Pantetheine, Coenzyme A, Holding company, Pharmaceutical industry

The sole agenda item of the Extraordinary General Meeting will be the election of Wouter Joustra as a new member of the Board of Directors.

Key Points: 
  • The sole agenda item of the Extraordinary General Meeting will be the election of Wouter Joustra as a new member of the Board of Directors.
  • Shareholders shall be represented at the Extraordinary General Meeting exclusively by the independent proxy.
  • For information on how to exercise rights and issue voting instructions to the independent proxy, shareholders can access the invitation to the Extraordinary General Meeting at www.edocumentview.com/VECT.
  • These statements include, but are not limited to, statements concerning the timing of the Extraordinary General Meeting.

Panavance Therapeutics to Present at the Pharma Partnering US Summit 2022

Retrieved on: 
Monday, November 14, 2022
FDA, Trial of the century, Respiration (physiology), Ed, AG, Therapy, Melanoma, Quality of life, Chemische Industrie Uithoorn, Ovarian cancer, Pancreatic cancer, Breast, Patient, Pharmaceutical industry, Panaveli

BERWYN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (Panavance or the Company), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the effectiveness of cancer treatments and quality of life for the patients that receive them, today announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics will present on Thursday, November 17, 2022 at 11:45 AM ET at the Pharma Partnering US Summit 2022 being held in Boston, MA.

Key Points: 
  • BERWYN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (Panavance or the Company), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the effectiveness of cancer treatments and quality of life for the patients that receive them, today announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics will present on Thursday, November 17, 2022 at 11:45 AM ET at the Pharma Partnering US Summit 2022 being held in Boston, MA.
  • In addition to the presentation, members of the executive leadership team will be available for in person meetings.
  • To schedule a meeting, please request through the conferences partnering platform.
  • Panavance Therapeutics Inc. is a privately-held, clinical-stage pharmaceutical company developing a novel oncology platform focused on improving the effectiveness of cancer treatments and quality of life for patients.

FilmTec®: First International Conference on the New Frontiers of Food Integration

Retrieved on: 
Thursday, November 24, 2022
Biotechnology, Vitamins, Supplements, Health, Fitness & Nutrition, Pharmaceutical, Athlete, Nutrition, CH, Cholecalciferol, Liverpool, Nutritional immunology, University, Research, Society, Liverpool John Moores University, Muscle, Foro Italico University of Rome, Melatonin, Pregnancy, Sport, IBSA, Pain, Saliva, Diet, Mouth, Vitamin, Ageing, Public health, Philosophy, Calcium, Capsule, Research and development, Food, Medicine, Vitamin D, Nutritional science, Vitamin B12, Exercise, Water, Inflammation, Health status of Asian Americans, Phosphorus, University of Milan, Vitamin D deficiency, Food science, Risk, CNEL, Metabolism, Dermatology, Quality, Division, Respiration (physiology), Absorption, Maintenance, Infection, B vitamins, CHF, Tablet, Associate, Reproductive medicine, Endocrinology, Dietary supplement, Epidemiology, EU

When a new technology is developed, the question is in which application it could be of real benefit.

Key Points: 
  • When a new technology is developed, the question is in which application it could be of real benefit.
  • In case of Oral Dispersible Films there are very marked features that facilitate this choice.
  • An effective solution to restore the right vitamin intake could be to take a food supplement which provides the recommended requirement.
  • Hence, the importance of being able to count on a new formulation, aligned with the expectations of the final consumer.

VectivBio to Present at the 2022 Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Respiration (physiology), Coenzyme A, Propionic acidemia, SBS, Nasdaq, Congenital disorders of amino acid metabolism, Short bowel syndrome, MMA, Community of Metros, Manufacturing execution system, Conference, Patient, Degenerative disease, Pantetheine, Pharmaceutical industry

BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will be presenting at the Jefferies London Healthcare Conference on Thursday, November 17, 2022.

Key Points: 
  • BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will be presenting at the Jefferies London Healthcare Conference on Thursday, November 17, 2022.
  • VectivBio is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions.
  • VectivBio is also advancing its modular, small molecule CoMET platform to address a broad range of previously undruggable Inherited Metabolic Diseases (IMDs).
  • Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA), propionic acidemia (PA), and other organic acidemias.

VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Retrieved on: 
Thursday, November 3, 2022
Patient, Pantetheine, Propionic acidemia, Compliance, Manufacturing execution system, Congenital disorders of amino acid metabolism, SBS, Respiration (physiology), Short bowel syndrome, GLOBE, FDA, Safety, PS, COVID-19, Nasdaq, Stoma, Study, Degenerative disease, STARS, Failure, U.S. Securities and Exchange Commission, Community of Metros, Forward-looking statement, Partnership, Drug development, Phrase, CIC, MMA, Security (finance), Coenzyme A, Medical imaging, Pharmaceutical industry

BASEL, Switzerland, Nov. 03, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the completion of enrollment of the Colon-in-Continuity (CIC) cohort for the company’s Phase 3 STARS (STudy of ApRglutide in SBS) pivotal study investigating the long-acting synthetic GLP-2 agonist apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF).

Key Points: 
  • This result is a testament to a successful operational effort based on our strong partnership with patients and investigators involved in this study.
  • STARS is a pivotal, global Phase 3 study enrolling approximately 144 patients with SBS-IF stratified 50/50 for CIC and stoma, with patients being evaluated over 48 weeks and 24 weeks respectively.
  • The study includes an improved PS weaning algorithm tailored to remnant bowel anatomy to enhance signal detection.
  • STARS is designed to establish a new standard of care for all patients with SBS-IF and to tailor apraglutide treatment to patients with distinct remnant bowel anatomy.